Under the terms of the cooperation agreement, Sanyou will leverage its globally renowned core technology platform to undertake integrated research and preclinical development for pioneering biological drugs
Sanyou, Sinorda Biomedicine collaborate on drug research and development. (Credit: Louis Reed on Unsplash)
Sanyou Biopharmaceuticals and Sinorda Biomedicine have entered into a strategic cooperation agreement to propel the progress of their innovative bispecific antibody drug project.
Under the terms of the cooperation agreement, Sanyou will leverage its globally renowned core technology platform to undertake integrated research and preclinical development for pioneering biological drugs. This will be complemented by Sinorda’s “super-trillion innovative biologics discovery platform.” The partnership capitalises on Sinorda’s extensive experience in preclinical and clinical oncology immunotherapy.
The primary objective of this collaboration is to jointly advance the research and development of their product pipeline through concerted efforts.
Sinorda CEO Pingsheng Hu said: “Sinorda focuses on the research and development of innovative drugs and industrialisation of oncology immunotherapy.
“Our partnership with Sanyou merges our strengths, accelerating the drug development process and transforming innovative achievements into reality faster.
“This collaboration improves treatment choices for patients. With this shared vision, we can work together to advance innovative drug products and contribute to human health.”
Sanyou CEO Guojun Lang said: “We’re truly honoured to establish strategic cooperation with Sinorda. Their strong scientific and medical expertise, robust clinical capabilities, and extensive experience in industrial collaboration perfectly align with Sanyou.
Both Sanyou and Sinorda share the common goal of using biopharmaceutical technology to enhance human health.
“Our combined strengths and robust collaboration will open new opportunities and forge a pioneering model of cooperation between innovative drug research and development services and pharmaceutical enterprises. Together, we are committed to delivering positive outcomes for patients worldwide.”